At the completion of this CPD activity, optometrists will understand the clinical utility of optical coherence tomography angiography (OCT-A), including:
Discern the benefits of OCT-A change analysis over time as a tool for earlier diagnosis of pathology of the retina and optic nerve.
Recognise common conditions where OCT-A imaging is clinically beneficial.
Understand the importance of choosing the appropriate OCT-A scan protocol and retinal layer appropriate to the suspected pathology.
Read More
Bayer’s aflibercept 8 mg recommended for approval in EU
Bayer’s higher dose aflibercept 8 mg with extended treatment intervals is set for approval in the European Union (EU) for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME).
Read More
Read More
How these Australian ophthalmologists maximise Optos ultra-widefield retinal imaging
Whether ophthalmologists are scanning a three-month-old or elderly patient, the ability of Optos ultra-widefield imaging devices to capture 200° of the retina in a single snapshot means pathology isn’t only detected – but is done so earlier to give patients the best chance of a positive outcome.
Read More
Read More
The Lancet publishes 24-month data for Apellis SYFOVRE GA therapy
Apellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating “that SYFOVRE is a clinically meaningful treatment” for the disease.
Read More
Read More
Apellis issues safety update after rare real-world retinal vasculitis reports
An investigation into rare events of retinal vasculitis linked to Apellis Pharmaceutical’s new therapy, SYFOVRE, for geographic atrophy (GA) has identified “internal structural variations” in a 19-gauge filter needle used to withdraw treatment from the vial.
Read More
Read More
New MDFA-TerryWhite partnership for early detection of AMD
Macular Disease Foundation Australia (MDFA) has teamed up with pharmacy chain TerryWhite Chemmart to raise awareness about the importance of monitoring changes in vision for early detection of macular disease.
Read More
Read More
IZERVAY Phase 3 clinical study achieves positive 24-month results
Astellas Pharma has announced positive 24-month topline results from the GATHER2 Phase 3 clinical study of IZERVAY, developed by its subsidiary Iveric Bio who recently secured regulatory approval in the US for the therapy.
Read More
Read More
Novartis discontinuing GT005 gene therapy clinical trial for geographic atrophy
Novartis will discontinue development of GT005 gene therapy, a subretinal injection for geographic atrophy (GA), in a blow to the global macular disease community, including Australia where the therapy was being trialled in some hospitals.
Read More
Read More
FDA clears higher dose Eylea; approvals sought in other markets
The US FDA has approved the use of high dose Eylea (aflibercept) for three macular conditions, equating to longer intravitreal injection intervals for patients.
Read More
Read More
Eyes for Life Canberra launches for blind and low vision community
Recently launched Eyes for Life Canberra aims to help people who are blind or have low vision to develop strategies that enable them to maximise their independence.
Read More
Read More